RECRUITING

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Talk to us

Conditions

Prostate CancerMagnetic Resonance ImagingPopulation at RiskScreening

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.

Official Title

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Quick Facts

Study Start:2022-08-15
Study Completion:2026-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05384535

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 55 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. PSA between 1.0 and 2.5 ng/dL
  2. 2. High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate cancer (father, brother) or specific genetic syndromes i.e. BRCA 1/2, HOX B13, Lynch syndrome, ATM, CHEK2
  3. 3. Patient is willing to participated in prostate cancer screening
  4. 4. Patient is capable of giving informed consent
  1. 1. Nodularity or firmness of prostate on exam
  2. 2. Patient has undergone a prior biopsy or prostate surgery
  3. 3. Patient is taking 5-alpha reductase inhibitors to manage benign prostatic hyperplasia, as this can significantly alter PSA levels.
  4. 4. Patient has a history of UTI or prostatitis in the preceding 6 months, as this can significantly alter PSA levels.
  5. 5. Patient has a contraindication to MRI, these include but are not limited to pacemakers, neurostimulator devices, metal cardiac valves, certain tattoos, or foreign bodies
  6. 6. Participants that experience claustrophobia, anxiety and/or vertigo when moved inside the scanner
  7. 7. The participant cannot tolerate lying flat for the study duration

Contacts and Locations

Study Contact

Cynthia Knauer, RN
CONTACT
516-734-8500
urologyresearch@northwell.edu
Monica Johnson
CONTACT
516-734-8500
urologyresearch@northwell.edu

Principal Investigator

Ardeshir Rastinehad, DO
PRINCIPAL_INVESTIGATOR
Northwell Health
Manish Vira, MD
PRINCIPAL_INVESTIGATOR
Northwell Health

Study Locations (Sites)

Cynthia Knauer
Lake Success, New York, 11042
United States

Collaborators and Investigators

Sponsor: Northwell Health

  • Ardeshir Rastinehad, DO, PRINCIPAL_INVESTIGATOR, Northwell Health
  • Manish Vira, MD, PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-15
Study Completion Date2026-10-31

Study Record Updates

Study Start Date2022-08-15
Study Completion Date2026-10-31

Terms related to this study

Keywords Provided by Researchers

  • Prostate Cancer
  • Screening
  • Magnetic Resonance Imaging

Additional Relevant MeSH Terms

  • Prostate Cancer
  • Magnetic Resonance Imaging
  • Population at Risk